Accordingly, the co-treatment of galunisertib with anti-PD-L1 treatment induced an immune response characterised with elevated T-bet and IFNγ levels in CD4+ T cells, increased GZMB production, along with increased infiltration into the tumours. The gene discussed is CD4; the disease is neoplasm.